EA202091630A1 - Дейтерированные соединения, композиции и способы для лечения раков, связанных с активацией etbr - Google Patents
Дейтерированные соединения, композиции и способы для лечения раков, связанных с активацией etbrInfo
- Publication number
- EA202091630A1 EA202091630A1 EA202091630A EA202091630A EA202091630A1 EA 202091630 A1 EA202091630 A1 EA 202091630A1 EA 202091630 A EA202091630 A EA 202091630A EA 202091630 A EA202091630 A EA 202091630A EA 202091630 A1 EA202091630 A1 EA 202091630A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- compositions
- treating cancer
- deuterated compounds
- cancer associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616729P | 2018-01-12 | 2018-01-12 | |
| PCT/US2019/013377 WO2019140324A1 (en) | 2018-01-12 | 2019-01-11 | Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091630A1 true EA202091630A1 (ru) | 2020-12-04 |
Family
ID=67212721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091630A EA202091630A1 (ru) | 2018-01-12 | 2019-01-11 | Дейтерированные соединения, композиции и способы для лечения раков, связанных с активацией etbr |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10435434B2 (https=) |
| EP (1) | EP3713571A4 (https=) |
| JP (1) | JP7539151B2 (https=) |
| KR (1) | KR102846292B1 (https=) |
| CN (1) | CN111886010A (https=) |
| AU (1) | AU2019206652B2 (https=) |
| CA (1) | CA3087009A1 (https=) |
| EA (1) | EA202091630A1 (https=) |
| MX (1) | MX2020007293A (https=) |
| WO (1) | WO2019140324A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10695400B2 (en) | 2015-08-03 | 2020-06-30 | Enb Therapeutics, Inc. | Compositions and methods for treating cancers associated with ETBR activation |
| AU2019206652B2 (en) * | 2018-01-12 | 2024-11-14 | Enb Therapeutics, Inc. | Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation |
| CN114423425A (zh) * | 2019-07-17 | 2022-04-29 | Enb治疗公司 | 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌 |
| TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
| EP4608447A1 (en) * | 2022-10-28 | 2025-09-03 | ENB Therapeutics, Inc. | Methods for treating cancers associated with etbr activation |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4874780A (en) * | 1987-03-11 | 1989-10-17 | Norsk Hydro A.S. | Anticancer compounds |
| US5496928A (en) | 1990-06-07 | 1996-03-05 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic substance |
| TW217417B (https=) | 1991-12-04 | 1993-12-11 | Manyu Seiyaku Kk | |
| EP0991660B8 (en) | 1997-10-08 | 2006-04-05 | Isotechnika,Inc. | DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| GB0223854D0 (en) | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| JP2006508086A (ja) | 2002-10-24 | 2006-03-09 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 固形腫瘍を予防および治療するための方法および組成物 |
| US7713440B2 (en) | 2003-10-08 | 2010-05-11 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
| WO2006019637A2 (en) | 2004-07-07 | 2006-02-23 | The Regents Of The University | An intelligent nanomedicine integrating diagnosis and therapy |
| US20080102451A1 (en) | 2006-10-31 | 2008-05-01 | Abbott Laboratories | Companion diagnostic assays for endothelin receptor antagonists |
| WO2008088727A2 (en) * | 2007-01-12 | 2008-07-24 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| US9289426B2 (en) | 2007-03-21 | 2016-03-22 | University Of Pennsylvania | Methods and compositions for treating solid tumors and enhancing tumor vaccines |
| US8303974B2 (en) | 2007-06-11 | 2012-11-06 | Edge Therapeutics, Inc. | Drug delivery system for the prevention of cerebral vasospasm |
| CN102170908A (zh) | 2008-08-29 | 2011-08-31 | 莱顿大学医学中心附属莱顿教学医院 | 向个体的肿瘤引流淋巴结递送cd40激动剂 |
| US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| ES2543280T3 (es) | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
| US20140341916A1 (en) | 2011-10-28 | 2014-11-20 | Genentech, Inc. | Therapeutic combinations and methods of treating melanoma |
| TWI613215B (zh) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| US10233277B2 (en) | 2012-03-02 | 2019-03-19 | The Governing Council Of The University Of Toronto | Polymeric nanoparticles useful in theranostics |
| WO2014025837A1 (en) | 2012-08-06 | 2014-02-13 | Board Of Regents, The University Of Texas System | Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors |
| WO2015095404A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| AU2014364606A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| WO2015110593A1 (en) | 2014-01-24 | 2015-07-30 | Cecilia Naucler | Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| RS61152B2 (sr) | 2015-05-12 | 2024-06-28 | Hoffmann La Roche | Terapeutski i dijagnostički postupci za lečenje raka |
| EP3763827A1 (en) | 2015-05-29 | 2021-01-13 | F. Hoffmann-La Roche AG | Pd-l1 promoter methylation in cancer |
| JP7144935B2 (ja) | 2015-05-29 | 2022-09-30 | ジェネンテック， インコーポレイテッド | 癌のための治療方法及び診断方法 |
| US10695400B2 (en) | 2015-08-03 | 2020-06-30 | Enb Therapeutics, Inc. | Compositions and methods for treating cancers associated with ETBR activation |
| JP6821693B2 (ja) | 2016-02-29 | 2021-01-27 | ジェネンテック， インコーポレイテッド | がんのための治療方法及び診断方法 |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| AU2019206652B2 (en) | 2018-01-12 | 2024-11-14 | Enb Therapeutics, Inc. | Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation |
| EP3746110A4 (en) | 2018-03-30 | 2022-03-02 | ENB Therapeutics, Inc. | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS AND USES |
| CN114423425A (zh) | 2019-07-17 | 2022-04-29 | Enb治疗公司 | 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌 |
| US20200289495A1 (en) | 2020-03-24 | 2020-09-17 | Enb Therapeutics, Inc. | Methods of inhibiting endothelin b receptor expressing tumor metastases |
| US20200268829A1 (en) | 2020-03-24 | 2020-08-27 | Enb Therapeutics, Inc. | Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer |
-
2019
- 2019-01-11 AU AU2019206652A patent/AU2019206652B2/en active Active
- 2019-01-11 EA EA202091630A patent/EA202091630A1/ru unknown
- 2019-01-11 CN CN201980018691.9A patent/CN111886010A/zh active Pending
- 2019-01-11 EP EP19738888.7A patent/EP3713571A4/en active Pending
- 2019-01-11 CA CA3087009A patent/CA3087009A1/en active Pending
- 2019-01-11 KR KR1020207022798A patent/KR102846292B1/ko active Active
- 2019-01-11 JP JP2020535980A patent/JP7539151B2/ja active Active
- 2019-01-11 MX MX2020007293A patent/MX2020007293A/es unknown
- 2019-01-11 US US16/246,398 patent/US10435434B2/en active Active
- 2019-01-11 WO PCT/US2019/013377 patent/WO2019140324A1/en not_active Ceased
- 2019-07-30 US US16/526,862 patent/US11066442B2/en active Active
-
2021
- 2021-06-17 US US17/350,497 patent/US12077604B2/en active Active
-
2024
- 2024-07-09 US US18/767,687 patent/US20240360173A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190218251A1 (en) | 2019-07-18 |
| US12077604B2 (en) | 2024-09-03 |
| JP2021510680A (ja) | 2021-04-30 |
| JP7539151B2 (ja) | 2024-08-23 |
| US20190345197A1 (en) | 2019-11-14 |
| KR102846292B1 (ko) | 2025-08-13 |
| US11066442B2 (en) | 2021-07-20 |
| MX2020007293A (es) | 2021-01-08 |
| EP3713571A1 (en) | 2020-09-30 |
| WO2019140324A1 (en) | 2019-07-18 |
| CA3087009A1 (en) | 2019-07-18 |
| US10435434B2 (en) | 2019-10-08 |
| US20240360173A1 (en) | 2024-10-31 |
| US20210309694A1 (en) | 2021-10-07 |
| KR20200119246A (ko) | 2020-10-19 |
| CN111886010A (zh) | 2020-11-03 |
| AU2019206652A1 (en) | 2020-07-16 |
| EP3713571A4 (en) | 2021-08-25 |
| AU2019206652B2 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091630A1 (ru) | Дейтерированные соединения, композиции и способы для лечения раков, связанных с активацией etbr | |
| CY1125358T1 (el) | Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων | |
| CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| CL2019001292A1 (es) | Nuevos derivados de quinolina. | |
| CL2020000301A1 (es) | Nuevos derivados de quinolina. | |
| EA202190189A1 (ru) | Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты | |
| EP3356522A4 (en) | COMPOSITIONS WITH PROTEIN-LOADED EXOSOME AND METHOD FOR THE PREPARATION AND RELEASE THEREOF | |
| MX378281B (es) | Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer. | |
| MX2020006010A (es) | Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos. | |
| MX419719B (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| CY1124504T1 (el) | Αντικαρκινικες συνθεσεις | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| MX372912B (es) | Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer. | |
| EP3439666A4 (en) | NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF | |
| EP3524267A4 (en) | THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTERING ANTI-HER2 ANTIBODIES / DRUG CONJUGATE | |
| MX393818B (es) | Terapias de combinación para el tratamiento de cáncer. | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| PY1570443A (es) | Anticuerpo drogas conjugados | |
| MX2017003638A (es) | Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos. | |
| MX2023008849A (es) | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. | |
| UY37800A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| EA201992612A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |